A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer

NCT07644286 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer (CRC)

Interventions

DRUG: Pirfenidone in combination with a PD-1 inhibitor
RADIATION: hypofractionated radiotherapy

Sponsor

Tao Zhang